Navigation Links
Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
Date:6/16/2008

was a phase II study of Schering Plough's CCR5 antagonist, vicriviroc, in highly treatment experienced HIV patients. This new analysis compared treatment outcomes based on the prospective selection of patients with R5 tropic virus by the original Trofile test versus treatment outcomes based on the re-classification using the enhanced version of the assay.

The ACTG 5211 study enrolled subjects who had R5 virus at screening as determined by the original Trofile assay. The analysis reported at this week's workshop demonstrated that recent enhancements to Trofile enable the assay to further optimize patient selection for CCR5 antagonist treatment by successfully identifying patients that experienced reduced virologic response to vicriviroc. In the patients originally identified as R5 tropic, based on test results obtained with the newly enhanced sensitivity of Trofile, greater reductions in viral load were observed in vicriviroc recipients confirmed to have pure R5 virus populations (1.95 log reduction at week 24) compared to those newly re-classified as having minor subpopulations of CXCR4-using virus (0.57 log reduction at week 24) (P<0.001).

Additional work described at the meeting focused on the use of Monogram's phenotypic and genotypic technology to identify specific markers of HIV resistance to new drug targets/classes. Monogram has assays in advanced development that accurately assess resistance to CCR5 antagonists such as maraviroc (Selzentry, Pfizer) and vicriviroc (Schering-Plough), and integrase inhibitors such as raltegravir (Isentress, Merck) and elvitegravir (Gilead Sciences).

Trofile, incorporating sensitivity enhancements, together with PhenoSense(TM), PhenoSenseGT(TM) and GeneSeq(TM) HIV drug resistance assays constitute Monogram's portfolio of assays for the optimization of antiretroviral therapy for HIV infection. Determining a patient's HIV profile at the molecular and phenotypic level, and the effect of therapy on that profile
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
2. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
3. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
4. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
5. Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research
6. Study Reaffirms Superiority of Trofile(TM) Assay
7. New York Medicaid Program Establishes Coverage for Trofile(TM)
8. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
9. ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
10. Assay Designs(TM) Announces Additions to the Leadership Team
11. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)...  US-Australian drug discovery company, Novogen, today announced ... with the Feinstein Institute for Medical Research (,Feinstein ... to collaborate with the objective of developing effective ... brings together the drug discovery expertise of Novogen ... Feinstein Institute in neurosciences and oncology. ...
(Date:4/17/2015)... WI (PRWEB) April 17, 2015 ... sales and marketing support for the powerful Orthogonal ... the Chemical Genomics Center at the Lankenau Institute ... LCGC’s mission is to measurably improve successful drug ... HTS, by offering rare, drug-like libraries available nowhere ...
(Date:4/16/2015)... Cambridge Semantics , the leading ... Web technology, and Informa , the leading ... the academic and scientific, professional and commercial business ... Data Lake for Clinical Trial and Competitive Intelligence’ ... ‘Best of Show’ Award. , The solution ...
(Date:4/16/2015)... 16, 2015 Proove Biosciences , ... of BIO Contest for the 2015 BIO International ... 2015 BIO International Convention will take place June 15-18 ... the Buzz of BIO contest, industry leaders will be ... at the conference. The community voting period began on ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) invites ... of the company,s 2008 investor meeting. The,corporate presentation ... Time on Thursday, March 13, 2008. The meeting ... of Jazz Pharmaceuticals, senior management team will provide ...
... Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") ... December 31, 2007., "2007 was our most ... the Company,s clinical trial program for REOLYSIN(R) with,Phase ... expanded and,initiated," said Dr. Brad Thompson, President and ...
... 6 Pathway Medical Technologies,which is developing innovative medical ... Buckman has been named as the new,Chairman of the ... been,acting Board Chairman since late 2006., "We are ... He brings,an extensive range of industry experience to the ...
Cached Biology Technology:Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 2Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 3Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 4Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 5Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 6Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 7Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 8Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 9Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors 2
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... antitumor drug could, in theory, shorten patients, long-term survival, comes ... suggests a potentially better option. The study appears in the ... (online April 27). Many cancer treatments work ... growing tumors. Agents that block a vessel-promoting factor called VEGF ...
... Philip E. Bourne, a computational biologist and professor with ... with the 2009 Benjamin Franklin Award this week in ... the free and open dissemination of science and scientific ... April 28, at the annual meeting of the Bioinformatics ...
... international agencies, including the director of the U.S. ... of cooperation that could reduce the number of ... The agreement between the United States, Canada, Japan ... scientific recommendations on alternative toxicity testing methods that ...
Cached Biology News:A longer lasting tumor blocker 2Open access advocate Philip E. Bourne to receive 2009 Benjamin Franklin Award 2Open access advocate Philip E. Bourne to receive 2009 Benjamin Franklin Award 3Countries unite to reduce animal use in product toxicity testing worldwide 2Countries unite to reduce animal use in product toxicity testing worldwide 3
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Inquire...
... Isoaspartate Detection Kit is intended for quantitative ... and peptides, which can result from the ... of aspartic acid residues during storage or ... on the monitoring of charge differences for ...
...
Biology Products: